PharmiWeb.com - Global Pharma News & Resources
11-Feb-2021

Breast Biopsy Market is growing at a CAGR of 5.3% from 2017 to 2023

Pune, Maharashtra, India, February 11 2021 (Wiredrelease) Allied Analytics –:Breast Biopsy Market Outlook – 2023

Allied Market Research recently published a report, titled, “The global breast biopsy market was valued at $977 million in 2016, and is projected to reach at $1,420 million by 2023, growing at a CAGR of 5.3% from 2017 to 2023. Core needle biopsy (CNB) segment accounted for about half of the global market share in 2016.”Asia-Pacific is anticipated to grow at a highest rate throughout the analysis period.

A breast biopsy is the procedure of locating a diseased tissue in the breast and collecting the specimen sample of the area for further examination and diagnosis. Breast biopsies are performed by using minimally invasive biopsy systems, owing to minimal disfigurement and pain. Non-invasive biopsy techniques provide preventive measures that assist physicians in diagnosing and treating high-risk breast cancer. This information prevents the application of chemotherapy in breast cancer, reducing the complexities of chemo-radiations. Vacuum assisted breast biopsy devices (VAB), core needle biopsies and fine needle aspiration biopsy are commonly used to perform biopsy procedures.

Do Enquiry for Sample Report@ https://www.alliedmarketresearch.com/request-sample/1067

COVID-19 scenario-

1) Due to the global pandemic all over the world, the medical devices manufacturers are majorly focusing on essential medical devices production including ventilators and diagnostics.

2) However, due to the precautionary measures taken by governments in various regions, the supply chain has been hampered. Which may result in shortage of devices in certain locations.

3) Food and Drugs Administration (FDA), on the other hand, shared a COVID-19 guidance with medical device manufacturers to notify the agency about changes that could affect availability of their products.

The core needle biopsy (CNB) segment dominated the global market in 2016, and is expected to maintain this trend throughout the analysis period, owing to the less invasive procedure compared to others and it provides more definitive diagnosis. Moreover, use of CNB and ultra sonographic and mammographic guidance is highly accurate for diagnosing breast cancer that supplements the market growth.

A breast biopsy is the procedure of locating a diseased tissue in the breast and collecting the specimen sample of the area for further examination and diagnosis. Breast biopsies are performed by using minimally invasive biopsy systems, owing to minimal disfigurement and pain. Non-invasive biopsy techniques provide preventive measures that assist physicians in diagnosing and treating high-risk breast cancer. This information prevents the application of chemotherapy in breast cancer, reducing the complexities of chemo-radiations. Vacuum assisted breast biopsy devices (VAB), core needle biopsies and fine needle aspiration biopsy are commonly used to perform biopsy procedures.

Asia-Pacific is anticipated to grow at a highest rate throughout the analysis period, owing to the continuous growth in countries, such as Japan, India, China, and Australia. For instance, in Japanese women between the age group of 30-64, breast cancer is one of the leading cancer types over the past decade. In addition, as per Japanese Society of Breast Health, one in every 20 women are diagnosed with breast cancer in Japan. This is a clear trend toward the increase in demand for breast biopsy procedures for screening and diagnosis of breast cancer at early stages. Furthermore, commandment by the government bodies for routine screening for breast cancer after the age of 40 for women has raised the demand for breast biopsy devices. Technological advancements for cost-effective devices in these nations offer a lucrative opportunity for the breast biopsy market growth.

Do Enquiry before purchasing Report@ https://www.alliedmarketresearch.com/purchase-enquiry/1067

Key Findings of the Breast Biopsy Market:

In 2016, core needle biopsy (CNB) led the overall breast biopsy market revenue, and is projected to grow at a CAGR of 5.6% during the forecast period.

The mammography guided stereotactic biopsy segment occupied the highest share among image guided technology in 2016, and is expected to grow at a CAGR of 5.6%.In 2016, 

North America generated highest revenue, region-wise, with over three-sevenths share of the global market.

The number of breast biopsy procedures is growing at a CAGR of 4.2% from 2017 to 2023.The ultrasound guided biopsy segment is expected to witness the highest growth rate from 2017 to 2023.

To know more about the report, visit the website at: https://www.alliedmarketresearch.com/Breast-Biopsy-market

Key players operating in the market include Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule medical Devices LLC., Ethicon Endo Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL.

Similar Reports With COVID-19 Impact:

Biomaterials Market : Global Opportunity Analysis and Industry Forecast 2020–2027

COPD and Asthma Devices Market : Global Opportunity Analysis and Industry Forecast 2020–2027

Advanced Wound Care Market : Global Opportunity Analysis and Industry Forecast 2020–2026

About Us: 

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

This content has been published by Allied Analytics company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at contact@wiredrelease.com.

Editor Details

Last Updated: 11-Feb-2021